|0.735 -0.061 (-7.66%)||12-08 16:00|
|Targets||6-month :||1.27||1-year :||1.75|
|Resists||First :||1.09||Second :||1.5|
|Supports||First :||0.43||Second :||0.35|
|MAs||MA(5) :||0.97||MA(20) :||0.77|
|MA(100) :||0.8||MA(250) :||1.31|
|MACD||MACD :||0.1||Signal :||0.1|
|%K %D||K(14,3) :||27.3||D(3) :||43.4|
|52-week||High :||2.91||Low :||0.4|
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.[ NRSN ] has closed above bottom band by 38.9%. Bollinger Bands are 270.4% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 8 days. This is a sign that the current trend might continue.
|If tomorrow:||Open lower||Open higher|
|High:||0.78 - 0.78||0.78 - 0.79|
|Low:||0.69 - 0.69||0.69 - 0.7|
|Close:||0.73 - 0.73||0.73 - 0.74|
NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of treatment for patients suffering from debilitating neurodegenerative diseases. Its lead product, PrimeC, is a novel oral formulation that has completed Phase IIa clinical trials for the treatment of amyotrophic lateral sclerosis. The company's preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel.
|Price to Book Value:
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
|Price to Earnings:
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
|Discounted cash flow:
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
|Return on Assets:
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
|Return on Equity:
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
|Debt to Equity:
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
|Shares Out||14 (M)|
|Shares Float||7 (M)|
|Held by Insiders||36.8 (%)|
|Held by Institutions||0.9 (%)|
|Shares Short||234 (K)|
|Shares Short P.Month||44 (K)|
|EPS Est Next Qtrly||0|
|EPS Est This Year||0|
|EPS Est Next Year||0|
|Book Value (p.s.)||-0.02|
|Profit Margin||0 %|
|Operating Margin||0 %|
|Return on Assets (ttm)||-114.6 %|
|Return on Equity (ttm)||-300.2 %|
|Qtrly Rev. Growth||0 %|
|Gross Profit (p.s.)||0|
|Sales Per Share||0|
|Qtrly Earnings Growth||0 %|
|Operating Cash Flow||0 (M)|
|Levered Free Cash Flow||0 (M)|
|Price to Book value||-36.75|
|Price to Sales||0|
|Price to Cash Flow||0|
|Dividend Pay Date||Invalid DateTime.|
|Ex-Dividend Date||Invalid DateTime.|